March 18, 2026
There's still time to get 50% off an annual STAT+ subscription. Becoming a subscriber supports our newsroom directly, and helps our commitment to uncompromising watchdog journalism — plus gives you special access to events, data tools, and more. Thanks for reading.
Molly Ferguson for STAT

STAT+ | How a Texas couple is getting rich off out-of-network medical bills

HaloMD says it gets medical providers what they deserve. Insurers claim fraud. STAT investigates how Scott and Alla LaRoque cashed in.

By Tara Bannow


STAT+ | FDA and NIH announce more initiatives to reduce animal testing in drug development

FDA released guidance to help drug companies assess their products without animals. NIH will offer grants to find alternatives.

By Lizzy Lawrence


As Trump administration cracks down on health care fraud, people with disabilities feel singled out

Disability advocates feel singled out by the Trump administration's fraud crackdown, warning that cuts to Medicaid and HCBS services risk lives and independence.

By O. Rose Broderick



APU GOMES/AFP via Getty Images

Opinion: Exposed and invisible in an ER hallway bed

Emergency department hallway beds have transformed the patient examination into a moral dilemma, leaving people exposed physically and emotionally.

By Jay Baruch


Premature menopause is linked to 40% increase in heart disease risk

JAMA Cardiology study says premature menopause, three times more common in Black women, is a risk factor for heart disease — but scientists aren't sure why.

By Elizabeth Cooney


More than 150,000 uncounted Covid-19 deaths occurred early in the pandemic, a study finds

The Covid-19 pandemic's early death toll was much higher than the official U.S. count, according to a new study.

By Associated Press


David Goldman/AP

Opinion: I was a surgeon. The hardest part of leaving medicine was believing that I could

Frances Mei Hardin, author of “Surgeon on the Edge,” on realizing how many options there are for physicians leaving medicine.

By Frances Mei Hardin


STAT+ | J&J wins approval for first-of-its-kind psoriasis pill

The FDA approval of Icotyde, a daily treatment, could roil a multibillion-dollar market, including AbbVie’s Skyrizi and J&J’s own Tremfya.

By Damian Garde


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.